Comparison of Outcomes and Access to Care for Heart Failure Trial (COACH)

October 4, 2022 updated by: Douglas Lee, Institute for Clinical Evaluative Sciences

Heart failure is a condition where the heart pump does not function normally causing the lungs to become congested. The primary symptom of heart failure is shortness of breath, and this often leads to patients visiting the emergency department for care. Decision-making in the emergency department is a high-stakes situation, where there is a need for decision support to guide clinicians to make better decisions about admission to hospital or discharge home. Many low-risk patients who could potentially be managed at home are admitted to hospital whereas some patients who are thought safe to discharge are actually high risk and will have adverse outcomes if they are discharged home from the emergency department.

In this trial, the investigators will study a new strategy for heart failure care, comprised of a computer algorithm to help doctors make decisions in the emergency department about the risk of their patient. For low-risk patients who are discharged home from the emergency department or after a short hospital stay, patients will be referred to a rapid follow-up clinic where the heart specialist team will rapidly assess and treat patients.

Study Overview

Status

Completed

Conditions

Detailed Description

Overview: Randomized intervention trial to examine the impact of an acute heart failure strategy, which incorporates risk stratification and rapid outpatient care after discharge.

Study Population: Patients presenting to the emergency department with heart failure will be eligible for study inclusion.

Inclusion and Exclusion Criteria for the Study:

  1. Age 18 years or older
  2. Presents to the emergency department with acute heart failure diagnosed clinically and verified by a primary diagnosis of heart failure (ICD-10-CA code I50) on the emergency department facesheet.

Exclusion criteria:

  1. Does not meet Framingham criteria for heart failure
  2. Heart failure diagnosis unlikely according to B-type natriuretic peptide values

    1. BNP <100 pg/mL or
    2. NT-proBNP <300 pg/mL
  3. End stage renal disease on dialysis
  4. Palliative patient with do not resuscitate (DNR) order present prior to emergency department arrival
  5. Limited mobility to attend outpatient clinic visits
  6. Dementia
  7. Nursing home resident
  8. No permanent home address
  9. Non-resident of Ontario
  10. Self-discharge from emergency department
  11. Invalid Ontario health insurance number

Inclusion and Exclusion Criteria for the RAPID-HF Clinic:

Inclusion criteria:

  1. Patients with heart failure presenting to the emergency department meeting overall study eligibility criteria
  2. Discharged at any time within the first 3 days after emergency department presentation
  3. Using the EHMRG30-ST risk score:

    1. Any low-risk patient who is able to be discharged within 3 days of initial emergency department presentation
    2. Some intermediate-to-low risk zone EHMRG30-ST may be eligible if judged to be clinically stable
  4. Patient agrees to be discharged early from either the emergency department or hospital
  5. Able to attend outpatient clinic visits

Exclusion criteria:

  1. High risk zone of EHMRG30-ST
  2. Pre-cardiac transplant
  3. Active cardiac ischemia without diagnostic testing done during hospital stay
  4. Uncontrolled arrhythmia
  5. Worsening renal failure compared to baseline renal function
  6. Significant abnormality of vital signs at the time of referral:

    1. Oxygen saturation on room air less than or equal to 90% which is not usual for patient
    2. Systolic blood pressure < 90 mmHg with symptoms of hypotension
    3. Heart rate in sinus rhythm greater than or equal to 100 bpm
    4. Respiratory rate > 20 breaths/minute
  7. New heart failure diagnosis (not an absolute contraindication to referral, but not recommended)

Intervention: The study involves 2 components: clinical algorithm for prognostication and post-discharge follow-up in the Rapid Ambulatory Program for Investigation and Diagnosis of Heart Failure (RAPID-HF) clinic.

The clinical decision-support algorithm intervention is a composite of 7-day and 30-day risk calculator (called EHMRG30-ST). Using the EHMRG30-ST algorithm, patients will be categorized as high, intermediate, or low risk. The decision support algorithm will recommend hospital admission or discharge/observation based on patient risk to assist clinicians making the final decision to admit or discharge. Low risk patients may be discharged early (within 3 days of initial presentation) and referred to the RAPID-HF clinic.

Patients referred to RAPID-HF will be assessed ideally within 48-72 hours of discharge. RAPID-HF provides transitional care for up to 30 days after discharge. After 30-days, care is transferred to primary care provider or specialist for ongoing care.

Study Design: Using a stepped-wedge design, participating sites will be randomized to the active intervention. At each step, hospitals that have not yet been randomized will serve as control sites.

Study Type

Interventional

Enrollment (Actual)

5452

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G2C4
        • Toronto Genera Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient presenting to an emergency department with heart failure

Exclusion Criteria:

  • Palliative or DNR
  • Dialysis dependent
  • Non-Ontario resident

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Intervention

Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic

Intervention #1 - Clinical algorithm: the EHMRG30-ST risk score which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation during a short stay hospital admission (3 days or less), or emergency department discharge.

Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48-72 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge.

Intervention consists of 2 components:

  1. Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores
  2. Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge.
No Intervention: Control
Usual care without access to the EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Co-primary outcome: 30 day early events
Time Frame: 30 days
Time to composite of death or cardiovascular hospitalization (nonelective, los > 1 day)
30 days
Co-primary outcome: 20 month extended events
Time Frame: 20 month follow-up
Time to composite of death or cardiovascular hospitalization (nonelective, los > 1 day)
20 month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause death
Time Frame: 30 days
Time to death
30 days
Cardiovascular hospitalization
Time Frame: 30 days
Time to cardiovascular hospitalization (nonelective, los > 1 day)
30 days
Heart failure hospitalization
Time Frame: 30 days
Time to heart failure hospitalization (nonelective, los > 1 day)
30 days
All-cause death
Time Frame: 20 months
Time to death (nonpalliative)
20 months
Cardiovascular hospitalization
Time Frame: 20 months
Time to cardiovascular hospitalization (nonelective, los > 1 day)
20 months
Heart failure hospitalization
Time Frame: 20 months
Time to heart failure hospitalization (nonelective, los > 1 day)
20 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient-centered outcome
Time Frame: 1) 30-day and 2) 20 month
Time to nonelective emergency department visit (CTAS 1-4), death or cardiovascular hospitalization
1) 30-day and 2) 20 month
Early discharge
Time Frame: 3 days
Proportion of patients discharged within 3 days of emergency presentation
3 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Douglas Lee, MD, PhD, University Health Network, Toronto

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2016

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

August 1, 2022

Study Registration Dates

First Submitted

January 29, 2016

First Submitted That Met QC Criteria

February 3, 2016

First Posted (Estimate)

February 4, 2016

Study Record Updates

Last Update Posted (Actual)

October 6, 2022

Last Update Submitted That Met QC Criteria

October 4, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2 (Other Identifier: Instituto Cardiovascular de Buenos Aires)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Due to Ontario privacy regulations, unable to share data

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Risk stratification and transitional care intervention

Subscribe